Co-Diagnostics says its COVID tests effective vs. omicron variant

LabPulse.com staff writers
Nov 28, 2021
2021 01 08 22 21 6464 Sars Co V 2 Rna 400

Utah-based molecular diagnostics firm Co-Diagnostics has confirmed that its existing line of COVID-19 polymerase chain reaction diagnostics remain effective in detecting the omicron coronavirus variant.

In a statement released by Co-Diagnostics, CEO Dwight Egan stated that the omicron variant, which has more than 50 mutations, does not interfere with the company's COVID-19 tests, including the following:

  • The Original Logix Smart COVID-19 assay
  • The SARS-CoV-2 2-gene test, the ABC (flu A/flu B/COVID-19) multiplex assay
  • The COVID-19 extraction-free direct saliva test
  • An in-development test to be used with an upcoming at-home/point-of-care device

The company also reported that it assessed the effectiveness of its products using publicly available sequencing data from the Global Initiative on Sharing All Influenza Data database.

Latest in COVID-19
Coronavirus Mutation Social
COVID-19’s 'long tail' analyzed at European rheumatology congress
May 31, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
May 11, 2023
Covid 19 Global Financial Crisis Social
NIH-backed project develops scoring system for identifying long-COVID patients
May 25, 2023
Money Bag Grant Award Social
Domus Diagnostics gets $2.4M NIH grant to develop at-home molecular test
May 24, 2023
Related Stories
2021 01 11 17 03 4617 Covid Diagnostic Test Kit 400
Financial Results
Co-Diagnostics shares drop on Q2 COVID revenues decline
2020 03 03 23 13 0226 Hepatitis C Virus 400
Collaboration
Co-Diagnostics joint venture approved for HCV test in India
2021 12 30 00 31 3981 Business Graph Money Stocks 400
Infectious
Co-Diagnostics reports record revenue in 2021
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in COVID-19
COVID-19’s 'long tail' analyzed at European rheumatology congress
EULAR’s 2023 Congress includes presentations on iRD patients’ susceptibility to long COVID, and COVID-19 vaccination safety in pregnant and breastfeeding women with autoimmune disease.
May 31, 2023
Coronavirus Mutation Social
FDA grants full approval for antiviral pill to treat mild-to-moderate COVID-19 in adults
Paxlovid is the fourth drug — and first antiviral pill — approved by the FDA to treat COVID-19 in adults.
May 25, 2023
Fda Button Social
NIH-backed project develops scoring system for identifying long-COVID patients
While multiple earlier studies have assessed the effects of long COVID, previous efforts largely had retrospective designs, relied on electronic health record entries, and lacked an uninfected comparison group.
May 25, 2023
Covid 19 Global Financial Crisis Social
Domus Diagnostics gets $2.4M NIH grant to develop at-home molecular test
The award, granted as part of the NIH Rapid Acceleration of Diagnostics (RADx) Tech program, will support accelerated validation and scaling of a testing platform to prepare it for a clinical trial.
May 24, 2023
Money Bag Grant Award Social
Medical records link vaccination against COVID-19 to reduced risk of non-respiratory symptoms
An analysis, details of which were presented Tuesday at the ATS 2023 International Conference in Washington, DC, reviewed data from 63,454 patients who were treated in a University of California medical center for COVID-19.
May 23, 2023
Covid 19 Vaccine Distribution Transport Social
Antibody titer levels associated with protection against Omicron: Study
Immunoglobin G and neutralizing antibody titer levels were associated with protection against infection with the Omicron variant and against symptomatic disease.
May 23, 2023
Covid 19 Antibody Social
Masking and air cleaners reduced COVID-19 in two Swiss schools: Study
Face masks and portable air cleaners effectively reduced the spread of SARS-CoV-2, the virus that causes COVID-19, in two Swiss schools.
May 18, 2023
Children Facemask School Social
Masking should continue in healthcare settings, some experts say
Masking in healthcare settings should continue in order to optimize patient safety, recommend infectious disease experts in a commentary.
May 16, 2023
Doctors Masks Team Social
LumiraDx Q1 revenues drop 82% as its transition from non-COVID tests takes shape
In April, the company had announced a cost restructuring program involving a reduction of its global workforce by approximately 40%. It now expects to see the full impact of the restructuring activities during the third quarter.
May 16, 2023
Covid 19 Financial Chart Social
A closer look at long COVID symptoms
Intensively studied patients with persistent post-COVID neurological symptoms were found to have autonomic dysfunction and differences in their immune cell profiles.
May 10, 2023
Long Covid Word Cloud Social
FDA grants de novo request enabling the marketing of QuidelOrtho SARS-CoV-2 antibody tests
The tests are intended for prescription use only for the qualitative detection of IgG antibodies to SARS-CoV-2 to aid in identifying patients who have an adaptive immune response to SARS-CoV-2 from either a recent or prior infection.
May 10, 2023
Covid 19 Antibody Social
Siemens Healthineers Q2 diagnostics revenues drop 39% on decline in rapid antigen test sales
The firm is seeing a return to low- to mid-single digital revenue growth as swings in demand from COVID-19 testing to routine testing normalize, Sharon Bracken, its president of diagnostics, said in an interview.
May 10, 2023
Business Intelligence Social
Page 1 of 32
Next Page